Phaseline

Companies › Azitra

Azitra: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ATR04-484
Engineered live biotherapeutic product (rLBP) containing S. epidermidis strain SE484
–Phase 1EGFR Inhibitor-associated RashJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06830863ATR04-484Phase 1EGFR Inhibitor-associated RashImmunologyJul 2027

From the company's SEC filings

Cash of $7m on 2026-06-30; operating cash outflow about $12m a year; runway about 7 months at that burn, to Jan 2027

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.